Alzchem Group AG

Alzchem Group AG

155.80
EUR
-1.90
(-1.20%)
6.67EPS
Oct 29Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
- -
- -
- -
34.78
36.87
36.96
37.27
41.62
53.5
53.16
54.47
55.62
57.74
Basic EPS, GAAP
-0.04
-0.04
-0.14
-0.13
2
2.23
1.77
1.94
2.72
2.96
3.4
5.31
6.28
6.65
Free Cash Flow per Basic Share
- -
- -
-0.22
-0.16
0.57
3.41
0.22
1.95
4.24
-0.42
7.15
10.33
13.56
6.58
Dividend per Share
- -
- -
- -
- -
1.75
1.1
0.9
0.75
0.77
1
1.05
1.2
1.8
3.9
Book Value per Share
- -
- -
- -
- -
5.47
6.58
5.87
6.57
8.65
14.21
15.88
20.25
25.32
26.66
Tangible Book Value per Share
- -
- -
- -
- -
5.37
6.5
5.72
6.4
8.42
13.92
15.52
19.89
24.97
26.29
Basic Weighted Avg Shares
- -
- -
- -
- -
10
10
10
10
10
10
10
10
10
10
Sales/Revenue/Turnover
- -
- -
- -
- -
354
375
376
379
422
542
541
554
562
584
Operating Margin (%)
- -
- -
- -
- -
9.49
10.53
7.93
8.53
8.82
5.6
10.53
14.1
16.54
17.27
Depreciation Expense
- -
- -
- -
- -
14
15
19
23
24
26
26
26
27
28
Net Income, GAAP
- -
- -
- -
- -
20
23
18
20
28
30
35
54
63
67
Effective Tax Rate (%)
- -
- -
- -
- -
29.87
28.62
28.81
26.96
23.96
26.79
27.8
28
27.64
27.43
Profit Margin (%)
- -
- -
- -
- -
5.76
6.03
4.78
5.19
6.53
5.54
6.4
9.76
11.29
11.52
Working Capital
- -
- -
- -
- -
62
61
70
73
76
83
134
156
178
194
LT Debt
- -
- -
- -
- -
19
33
58
55
43
32
52
43
36
82
Total Equity
- -
- -
- -
- -
58
68
61
69
90
146
164
207
258
272
Return on Invested Capital (%)
- -
- -
- -
- -
44.94
23.83
15.82
16.77
31.74
22.07
16.64
21.6
22.52
24.7
Return on Capital (%)
- -
- -
- -
- -
44.88
21.62
16.64
16.47
20.3
16.4
16.93
23.89
23.8
24.32
Return on Common Equity (%)
-251.36
- -
- -
- -
73.26
36.93
28.37
31.1
35.71
25.95
22.65
29.46
27.48
27.32

Capital Structure

EUR

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
8
- -
8
LT Borrowings
35
- -
82
LT Finance Leases
1
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
10
10
10
Market Capitalization
- -
- -
- -

Working Capital

EUR

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
297
316
308
Cash, Cash Equivalents & STI
76
69
66
Accounts Receivable, Net
73
86
96
Inventories
116
123
110
Total Current Liabilities
119
139
114
Payables & Accruals
- -
- -
- -
ST Debt
8
- -
8
Deferred Revenue
- -
- -
- -

Growth Rates

EUR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
31.36%
24.47%
Free Cash Flow
-1,670.85%
-346.48%
30.31%
Net Income, GAAP
-7,089.59%
27.55%
17.35%
Sales/Revenue/Turnover
- -
8.68%
1.42%
Total Cash Common Dividend
- -
20.15%
48.95%

Quarterly Revenue

EUR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
150
136
129
139
554
2025
145
143
- -
137
562
2026
149
155
- -
- -
- -

Quarterly Earnings Per Share

EUR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1.2
1.41
1.22
1.49
5.31
2025
1.44
1.57
- -
1.66
6.28
2026
1.77
1.66
- -
- -
- -

Quarterly Dividends Per Share

EUR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
1.2
- -
- -
1.2
2025
- -
1.8
- -
- -
1.8
2026
- -
2.1
- -
- -
- -

Company Description

CEO
Andreas Niedermaier
Full Time Employees
1,765
Sector
Process industries
Industry
Chemicals: major diversified
Address
Dr.-Albert-Frank-Strasse 32 Trostberg BV Germany 83308
IPO Date
Sep 9, 2026
Business
Alzchem Group AG is a globally active specialty chemicals company that develops, produces and markets products based on the calcium carbide and calcium cyanamide value chain, with operations organized across Specialty Chemicals, Basics & Intermediates, and Other & Holding segments. Founded in 1908 and headquartered in Trostberg, Germany, the company serves customers in nutrition, agriculture, fine chemicals, renewable energy, metallurgy and industrial applications. Its core portfolio includes dietary supplements and ingredients such as Creapure and Creavitalis; specialty feed and food ingredients; epoxy curing agents under the DYHARD brand; silicon nitride under the SILZOT brand for advanced ceramics and solar wafers; technical gases; fertilizer and agrochemical products, including germicides, plant growth regulators and plant protection additives; as well as other chemical intermediates and carbide-based products. Alzchem operates primarily in Europe and also serves international markets through its sales and production network, with the group’s parent company and key operating subsidiaries located in Trostberg, Germany. In recent periods, the company has accelerated its strategic shift toward higher-value specialty chemicals and ingredients, including record sales and EBITDA in fiscal 2025, a planned increase in the dividend, and continued expansion of its creatine business. Alzchem and Ehrmann launched a cooperation in 2025 to expand high-protein products using Creavitalis, while the company also advanced capacity expansions for guanidine nitrate and nitroguanidine in Germany and continued site selection for a new nitroguanidine plant in the United States. In addition, Alzchem approved a new investment program of around EUR 120 million for a largely automated creatine production plant and related infrastructure, with gradual commissioning planned from the second half of 2027, underscoring its focus on profitable growth and capacity expansion.

Company News

  • AlzChem Group AG (ALZCF) Q2 2026 Earnings Call Transcript

  • AlzChem Group AG (ALZCF) Q1 2026 Earnings Call Transcript

  • AlzChem Group AG (ALZCF) Q4 2025 Earnings Call Transcript